Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$5.8M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$134M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| Fahey Sandell Jacquelyn | Oct 2, 2024 | Sell | 5,999 | $5.82 | $35,000 |
| Sandrock Alfred | Apr 2, 2024 | Sell | 12,115 | $9.86 | $120,000 |
| Swartz Robin | Apr 2, 2024 | Sell | 1,357 | $9.88 | $13,000 |
| Sandrock Alfred | Feb 21, 2024 | Sell | 13,033 | $7.46 | $97,000 |
| Swartz Robin | Feb 21, 2024 | Sell | 3,966 | $7.45 | $30,000 |
| PFREUNDSCHUH PETER P. | Feb 21, 2024 | Sell | 3,764 | $7.46 | $28,000 |
| Carter Todd Alfred | Feb 21, 2024 | Sell | 3,365 | $7.47 | $25,000 |
| Carter Todd Alfred | Feb 20, 2024 | Sell | 602 | $7.68 | $4,600 |
| Swartz Robin | Jan 17, 2024 | Sell | 2,543 | $7.15 | $18,000 |
| Carter Todd Alfred | Jan 17, 2024 | Sell | 1,266 | $7.18 | $9,100 |
| PFREUNDSCHUH PETER P. | Oct 3, 2023 | Sell | 13,567 | $6.99 | $95,000 |
| Carter Todd Alfred | Sep 15, 2023 | Sell | 10,500 | $8.16 | $86,000 |
| Carter Todd Alfred | Jul 6, 2023 | Sell | 5,500 | $10.8 | $59,000 |
| Carter Todd Alfred | Jun 30, 2023 | Sell | 5,000 | $11.41 | $57,000 |
| Sandrock Alfred | Apr 3, 2023 | Sell | 7,437 | $7.83 | $58,000 |
| Swartz Robin | Apr 3, 2023 | Sell | 1,259 | $7.83 | $9,900 |
| Carter Todd Alfred | Mar 20, 2023 | Sell | 2,193 | $7.76 | $17,000 |
| Swartz Robin | Mar 20, 2023 | Sell | 3,654 | $7.76 | $28,000 |
| Hesslein Robert W. | Mar 20, 2023 | Sell | 4,410 | $7.76 | $34,000 |
| Swartz Robin | Mar 15, 2023 | Sell | 15,373 | $8.2 | $130,000 |
| NEUROCRINE BIOSCIENCES INC | Feb 23, 2023 | Buy | 4,395,588 | $8.88 | $39M |
| Hesslein Robert W. | Feb 17, 2023 | Sell | 3,297 | $7.45 | $25,000 |
| Carter Todd Alfred | Feb 17, 2023 | Sell | 738 | $7.45 | $5,500 |
| Hesslein Robert W. | Feb 13, 2023 | Sell | 2,868 | $7.67 | $22,000 |
| Carter Todd Alfred | Feb 13, 2023 | Sell | 797 | $7.67 | $6,100 |
| TEPPER ROBERT I | Feb 1, 2023 | Sell | 128,642 | $9.32 | $1.2M |
| TEPPER ROBERT I | Jan 31, 2023 | Sell | 185,000 | $9.25 | $1.7M |
| TEPPER ROBERT I | Jan 30, 2023 | Sell | 75,000 | $9.03 | $680,000 |
| TEPPER ROBERT I | Jan 27, 2023 | Sell | 50,000 | $9.02 | $450,000 |
| TEPPER ROBERT I | Jan 25, 2023 | Sell | 50,000 | $9.22 | $460,000 |
| TEPPER ROBERT I | Jan 24, 2023 | Sell | 100,000 | $9.27 | $930,000 |
| TEPPER ROBERT I | Jan 23, 2023 | Sell | 55,000 | $9.06 | $500,000 |
| TEPPER ROBERT I | Jan 20, 2023 | Sell | 100,000 | $9.15 | $920,000 |
| Hesslein Robert W. | Jan 17, 2023 | Sell | 1,396 | $9.57 | $13,000 |
| Swartz Robin | Jan 17, 2023 | Sell | 1,396 | $9.57 | $13,000 |
| Hesslein Robert W. | Jan 17, 2023 | Sell | 792 | $10.34 | $8,200 |
| Carter Todd Alfred | Jan 17, 2023 | Sell | 706 | $9.57 | $6,800 |
| Carter Todd Alfred | Jan 17, 2023 | Sell | 400 | $10.34 | $4,100 |
| Swartz Robin | Jan 17, 2023 | Sell | 792 | $10.34 | $8,200 |
| EcoR1 Capital, LLC | Jan 11, 2023 | Sell | 110,000 | $8.4965 | $930,000 |
| EcoR1 Capital, LLC | Jan 10, 2023 | Sell | 336,400 | $8.0542 | $2.7M |
| EcoR1 Capital, LLC | Jan 9, 2023 | Sell | 456,000 | $7.6717 | $3.5M |
| Carter Todd Alfred | Jan 6, 2023 | Sell | 388 | $6.41 | $2,500 |
What's the latest insider transaction for Voyager Therapeutics?
The most recent insider transaction for Voyager Therapeutics was conducted by Fahey Sandell Jacquelyn, who sold 5,999 shares on October 2, 2024 at a price of $5.82 per share.
Which insider bought the most VYGR stock over the last two years?
NEUROCRINE BIOSCIENCES INC has bought the most VYGR stock in the last 2 years, with a total value of $39M.
Which insider has sold the most VYGR stock over the last two years?
EcoR1 Capital, LLC has sold the most VYGR stock in the last 2 years, with a total value of $7.1M.
What is the total value of insider transactions for Voyager Therapeutics (VYGR) in the last 2 years?
According to our estimates, the total value of insider transactions for Voyager Therapeutics in the last 2 years is positive, amounting to $24M. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
How do insider transactions over the last 2 years reflect on Voyager Therapeutics' market confidence?
Over the last 2 years, insider transactions for Voyager Therapeutics have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
